FDAsafety guidance72% confidence
S6 (R1) Addendum: Preclinical Safety Evaluation of Biotechnology - Derived Pharmaceuticals
Source: FDA
Why This Matters
Why this matters: illustrates how regulators handled a comparable safety guidance decision relevant to Orbit Pharma Limited.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Neurology · Antiemetic
- Sub-indication
- General
Related signal: Orbit Pharma recalls Cyclizine Lactate due to GMP deficiencies